Obsidian Therapeutics grants options to director

Barrett Peter reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 08/05/2026 - 04:07 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Barrett Peter reported acquisition or exercise transactions in this Form 4 filing.

Obsidian Therapeutics, Inc. director Peter Barrett received a grant of stock options for 37,653 shares of common stock, exercisable at $12.00 per share. These options expire on August 2, 2036 and represent his entire reported derivative holding after the grant. The options vest and become exercisable upon the earlier of the one-year anniversary of the grant date or the company’s next annual meeting of stockholders, conditioned on his continued service.

Insider Trade Summary

Grant/Award: 37,653 shares

Grant/Award 1 txn

Insider Barrett Peter

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	37,653	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 37,653 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the Issuer's annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date.

Key Figures

Options granted: 37,653 shares Exercise price: $12.00 per share Expiration date: August 2, 2036 +1 more

4 metrics

Options granted 37,653 shares Stock Option (Right to Buy) granted to director Peter Barrett

Exercise price $12.00 per share Conversion or exercise price of the stock option grant

Expiration date August 2, 2036 Option expiration for the 37,653-share grant

Derivative shares after transaction 37,653 Total derivative securities beneficially owned following the grant

Key Terms

Stock Option (Right to Buy), exercise price, vest and become exercisable, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"Security title listed as Stock Option (Right to Buy) for the grant"

exercise price financial

"Conversion or exercise price of the option is $12.0000 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become exercisable financial

"The shares underlying this option shall vest and become exercisable upon the earlier of"

annual meeting of stockholders financial

"earlier of the one-year anniversary of the grant date or the date of the Issuer's annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Obsidian Therapeutics (OBX) director Peter Barrett report in this Form 4?

Peter Barrett reported a grant of stock options for 37,653 shares of Obsidian Therapeutics common stock. The options were awarded at an exercise price of $12.00 per share and are his only derivative holdings reported after this transaction.

What is the exercise price and size of the new OBX stock option grant?

The new stock option grant covers 37,653 shares of Obsidian Therapeutics common stock at an exercise price of $12.00 per share. This means Barrett may purchase up to that number of shares at $12.00 once vested and exercisable.

When do Peter Barrett’s new Obsidian Therapeutics (OBX) options vest?

The options vest upon the earlier of one year after the grant date or the date of Obsidian Therapeutics’ next annual meeting of stockholders, provided Barrett continues serving the company through that vesting date.

When do the newly granted OBX stock options to Peter Barrett expire?

The stock options granted to Peter Barrett expire on August 2, 2036. After this expiration date, any unexercised portion of the 37,653-share option grant can no longer be exercised to purchase Obsidian Therapeutics common stock.

How many Obsidian Therapeutics (OBX) options does Peter Barrett hold after this grant?

After this grant, Barrett holds 37,653 stock options as reported derivative securities. The Form 4 lists this amount as the total derivative shares following the transaction, all tied to the newly granted option award.

Is Peter Barrett’s OBX option grant under a Rule 10b5-1 trading plan?

The Form 4 indicates the Rule 10b5-1 checkbox is not marked, so this stock option grant is not reported as being made under a Rule 10b5-1 trading plan. It is disclosed as a compensation-related award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Barrett Peter

(Last) (First) (Middle)

C/O OBSIDIAN THERAPEUTICS, INC.

1030 MASSACHUSETTS AVE

(Street)

CAMBRIDGE MASSACHUSETTS 02138

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Obsidian Therapeutics, Inc. [ OBX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12	08/03/2026		A		37,653		(1)	08/02/2036	Common Stock	37,653	$0	37,653	D

Explanation of Responses:

1. The shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the Issuer's annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date.

	/s/ Gabriela Morales-Rivera, Attorney-in-Fact	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)